Association Between the Thr325Ile and Ala147Thr Polymorphisms of the TAFI Gene and the Risk of Venous Thromboembolic Disease

Abstract

References

Schatteman K. , Goossens F. , Leurs J. , et al. Carboxypeptidase U at the interface between coagulation and fibrinolysis. Clin Appl Thromb Hemost 2001;7:93-101.

Eichinger S. , Schonauer V. , Weltermann A. , et al. Thrombin activatable fibrinolysis inhibitor and the risk for recurrent venous thromboembolism. Blood 2004;103: 3773-3776.

Zee RY , Hegener HH , Ridker PM Carboxypeptidase B2 gene polymorphisms and the risk of venous thromboembolism . J Thromb Haemost 2005;12:2819-2821.

Martini CH , Brandts A. , de Bruijne EL , et al. The effect of genetic variants in the thrombin activatable fibrinolysis inhibitor (TAFI) gene on TAFI-antigen levels, clot lysis time and the risk of venous thrombosis. Br J Haematol 2006;134:92-94.

Verdu J. , Marco P. , Benlloch S. , Sanchez J. , Lucas J. Thrombin activatable fibrinolysis inhibitor (TAFI) polymorphisms and plasma TAFI levels measured with an ELISA insensitive to isoforms in patients with venous thromboembolic disease (VTD). Thromb Haemost 2006; 95:585-586.